Myomo Inc. · AMEX:MYO
Myomo — Investor Presentation (May 2025)
25 slides from Myomo's investor presentation, May 2025
Slide 1: Investor Presentation May 2025
INVESTOR PRESENTATION MAY 2025 Paul R. Gudonis, Chairman and CEO David Henry, CFO Conquering Upper Limb Paralysis with Wearable Medical Robotics NYSE American: MYO 1
Slide 2: Legal Disclaimer
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and
Slide 3: It's a new world for people suffering from upper extremity impairment
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials It’s a new world for people suffering from upper extremity impairment 3
Slide 4: Investment Highlights
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Investment Highlights 1 2 3 Up to 600,000+ Patient First-Mover Advantage in a CMS Reimbursement Fees Prevalence Population – Large and Growing Market Opens Access to Large Equating to a Sizable
Slide 5: Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease Stroke TBI Major Dx Other Dx SCI Stroke/CVA Cerebral Palsy Traumatic Brain BPI Multiple Sclerosis Injury PI ALS Sp
Slide 6: Myomo Addresses an Unmet Need that Existing Upper Extremity Treatments Don't
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Myomo Addresses an Unmet Need that Existing Upper Extremity Treatments Don’t Current Treatment Options Rehabilitation: The Medical Need: ➢ Occupational therapy ➢ Static bracing A lightweight, p
Slide 7: Stroke TBI SCI
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Stroke TBI SCI BPI PI 7
Slide 8: Substantial Market Opportunity
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Substantial Market Opportunity Senior Insured Population Up to 50,000 We believe the TAM for Up to patients 600,000 replenish the the MyoPro approximately patients may 46% prevalence doubles wi
Slide 9: Clarity on Reimbursement
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Clarity on Reimbursement HCPCS Codes L8701, L8702 for MyoPro Issued January 2019 As of January 1, 2024, these codes are in the brace benefit category, meaning lump sum reimbursement Effec
Slide 10: Reimbursement Status: International Markets
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Reimbursement Status: International Markets Germany: Reimbursement for the MyoPro is on a case-by-case basis, with insurance companies often paying for a six-month trial to demonstrate the bene
Slide 11: Recent Clinical Research Accepted for Publication
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Recent Clinical Research Accepted for Publication Myoelectric Arm Orthosis Assists Functional Activities: A 3-Month Home Use Outcome Report Results: Statistically significant and clinically mea
Slide 12: Enabling a Paralyzed Arm to Move Again
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Enabling a Paralyzed Arm to Move Again 12
Slide 13: MyoPro Powered Arm Brace: Only Device to Restore Function
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials MyoPro Powered Arm Brace: Only Device to Restore Function ➢ MyoPro uses advanced sensor technology as a brain-computer interface to detect the user’s intention to move via the body’s electromyo
Slide 14: Go-to-Market Approach: How a Patient Obtains a MyoPro
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Go-to-Market Approach: How a Patient Obtains a MyoPro Lead Generation Reimbursement MyoPro Custom Delivery & & Evaluation Approval Fabrication Payment New MyoPro 2+ Remote Measurement Referral
Slide 15: Cost-Effective TV Advertising for Target Demographic
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Cost-Effective TV Advertising for Target Demographic 14
Slide 16: Go-to-Market Approach: Multi-Channel, Emphasis on Direct Billing and International Sales
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Go-to-Market Approach: Multi-Channel, Emphasis on Direct Billing and International Sales Q1 2025 Product Revenue % 3% Sales Channels: With Medicare 13% Reimbursement, 5% we are re-engaging the
Slide 17: Direct Billing and Delivery
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials With Reimbursement in Place, We Are Developing a Nationwide Network of MyoPro Centers of Excellence (COE’s) O&P Clinics (COE’s) Payers • Medicare-Accredited Partners $ • In-Network with Payers
Slide 18: International Update: Activity in Key Markets
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials International Update: Activity in Key Markets China JV company established - 19.9% Equity Interest for MYO shareholders China patents issued Clinical trials underway Strong growth in Germany si
Slide 19: Key Metrics: Pipeline and Backlog
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Key Metrics: Pipeline and Backlog Pipeline Backlog 1600 1400 350 316 1200 300 275 282 272 249 1000 1482 250 230 800 200 1112 150 600 100 400 50 200 0 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 0 3/31/
Slide 20: Strong Revenue Growth Continued in First Quarter
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Strong Revenue Growth Continued in First Quarter Quarterly Product Revenue 14,000,000 12,000,000 10,000,000 8,000,000 6,000,000 4,000,000 2,000,000 0 1Q 2Q 3Q 4Q 2020 2021 2022 2023 2024 2025 N
Slide 21: P&L and Key Balance Sheet Metrics
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials P&L and Key Balance Sheet Metrics P&L Key Balance Sheet Metrics Actual Actual Actual Actual Actual Actual ($000's) Q1'25 Q1'24 2024 2023 ($000's) Q1'25 Q4'24 Product Revenue $ 9,832 $ 3,754 $ 3
Slide 22: Key Milestones Driving Revenue Growth
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Key Milestones Driving Revenue Growth Revenues Invest in $M Direct Billing Channel 50-53 Medicare China JV Part B license revenues revenue, Record 32.6 Record Int’l Int’l Expanded # and VA Pivo
Slide 23: Strategic Plan to Achieve Revenue Growth
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Strategic Plan to Achieve Revenue Growth Expected Increased Marketing, Payer Contracts, International Expansion, Medicare Reimbursement, and Broader O&P Channel for Anticipated Revenue Growth 2
Slide 24: Leadership Team & Board of Directors
Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Leadership Team & Board of Directors Management Team Members Board of Directors Paul R. Gudonis Barry Camrell Thomas Kirk Chairman & CEO Lead Independent Director VP of QA/RA Scaled multiple te
Slide 25: Thank You! For Additional Information
Thank You! For Additional Information: Paul R. Gudonis, CEO David Henry, CFO paul@myomo.com david.henry@myomo.com 617-401-2623 508-344-5235 25